Bionano Story

Our latest forecast of Bionano (NASDAQ:BNGO)
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Bionano Genomics. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Bionano Genomics

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Bionano Genomics' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Bionano Genomics in the context of predictive analytics.

Hype Prediction Details

Intrinsic Valuation Details

Naive Forecast Details

4 Analysts Consensus Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Bionano Genomics. Your research has to be compared to or analyzed against Bionano Genomics' peers to derive any actionable benefits. When done correctly, Bionano Genomics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Bionano Genomics.

How important is Bionano Genomics's Liquidity

Bionano Genomics financial leverage refers to using borrowed capital as a funding source to finance Bionano Genomics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Bionano Genomics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Bionano Genomics's total debt and its cash.

How Bionano utilizes its cash?

To perform a cash flow analysis of Bionano Genomics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Bionano Genomics is receiving and how much cash it distributes out in a given period. The Bionano Genomics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Bionano Genomics Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (28.67 Million)

Acquisition by Chaubey Alka of 300000 shares of Bionano Genomics subject to Rule 16b-3

Legal trades by Bionano Genomics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Bionano insider trading alert for grant of stock option (right to buy) by Chaubey Alka, Chief Medical Officer, on 11th of October 2020. This event was filed by Bionano Genomics Inc with SEC on 2020-09-03. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Bionano Genomics Indicators

About Contributor